Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes

Inclusion Criteria: * Type 1 diabetes mellitus * HbA1c (glycosylated haemoglobin) maximum 9.0% * Duration of diabetes at least 1 year * Body Mass Index (BMI) maximum 25.0 kg/m\^2 Exclusion Criteria: * Recurrent severe hypoglycaemia * Proliferative retinopathy or maculopathy requiring acute treatment as judged by the Investigator * Impaired hepatic function * Impaired renal function * Cardiac problems * Uncontrolled treated / untreated hypertension * Hepatitis B surface antigen, Hepatitis C antibodies or HIV (human immunodeficiency virus) antibodies, positive * Known or suspected allergy against the trial products or related products including the components * Previous history of serious allergy or anaphylactic reaction * Any disease or condition which the Investigator feel would interfere with the trial participation or evaluation of the results * Severe late-phase diabetic complications including nephropathy * Blood donation of more than 400 mL (inclusive) in total within the last 12 weeks or more than 200 mL (inclusive) in total within the last 3 weeks * Known or suspected alcohol and illicit substance abuse or dependence * Pregnancy, breast-feeding (within a year after labour) or the intention to become pregnant * The receipt of any investigational drug within the last 12 weeks prior to this trial * Current or anticipated treatment with systemic corticosteroids